Gerardelli, L., Demanche, A., Lebrun, M., Bottero, B., Bosmans, M., Havrics, E., Perin, F., Morbidelli, M., Peiffer, R., Crake, R., La Rocca, R., Marichal, T., Nokin, M.-J., & Cataldo, D. (24 April 2026). Targeting the CCL5-CCR5 Axis: A New Strategy Against Chemoresistant Mesothelioma [Poster presentation]. Predict Meso. |
Morbidelli, M. (2026). Inhibition of ADAM10 targeted to mesothelioma: development of a Dual Targeting protein [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/344204 |
Gerardelli, L., Demanche, A., Lebrun, M., Bottero, B., Bosmans, M., Havrics, E., Perin, F., Morbidelli, M., Peiffer, R., Crake, R., La Rocca, R., Marichal, T., Nokin, M.-J., & Cataldo, D. (20 March 2026). Targeting the CCL5-CCR5 Axis: A New Strategy Against Chemoresistant Mesothelioma [Poster presentation]. 24th Lung Science Conference, Estoril, Portugal. |
Morbidelli, M. (06 June 2024). Dual-targeting protein against ADAM-10 and Mesothelin: The next generation anticancer agent for mesothelioma [Paper presentation]. Seminar Metabolism & Cardiovascular Biology, Liège, Belgium. |
Morbidelli, M., Lassaux, P., Dumoulin, M., & Cataldo, D. (30 May 2024). Dual-targeting protein against ADAM-10: The next-generation anticancer agent for mesothelioma [Poster presentation]. PhD Students' day, Louvain-la-Neuve, Belgium. |
Morbidelli, M., Cataldo, D., Lassaux, P., Dumoulin, M., & Redeghieri, P. (18 September 2023). Characterization of a nanobody against mesothelin: a new way to defeat Mesothelioma [Poster presentation]. Single-Domain Antibodies 2023, Paris, France. |
Morbidelli, M., Cataldo, D., Lassaux, P., & Dumoulin, M. (04 September 2023). Characterization of a nanobody against mesothelin: a new way to detect/defeat Mesothelioma [Poster presentation]. GIGA Day 2023, Liège, Belgium. |
Morbidelli, M., Cataldo, D., Lassaux, P., & Dumoulin, M. (01 June 2023). Production and characterization of a Disintegrin and Metalloproteinase 10 (ADAM10): a protease involved in body homeostasis and cancer progression [Paper presentation]. BeRS-GSK Awards 2023, Brussels, Belgium. |
Morbidelli, M. (25 May 2023). Characterization of a nanobody against Mesothelin [Paper presentation]. GIGA Cardiovascular Seminar, Liège, Belgium. |
Morbidelli, M., Cataldo, D., Lassaux, P., & Dumoulin, M. (13 October 2022). Introduction and characterization of a Disintegrin and Metalloproteinase 10 (ADAM10): a protease involved in cancer progression [Poster presentation]. 2nd DiSVA-MaSBiC Annual Symposium "protein structure and function in Biology, Medicine and Nanotechnology", Ancona, Italy. |
Morbidelli, M. (06 October 2022). Production and characterization of A Disintegrin and Metalloproteinase 10 (ADAM10): a protease involved in body homeostasis and cancer progression [Paper presentation]. GIGA - Cardiovascular sciences seminar, Liège, Belgium. |
Morbidelli, M., Cataldo, D., Dumoulin, M., & Lassaux, P. (17 September 2022). Production and characterization of A Disintegrin and Metalloproteinase 10 (ADAM10): a protease involved in body homeostasis and cancer progression [Poster presentation]. FEBS-ICGEB 2022 Advanced Course "proteolysis: at the interface between health and disease", Bled, Slovenia. |
Morbidelli, M., Cataldo, D., Lassaux, P., & Dumoulin, M. (06 September 2022). Anti Mesothelin VHH: A single domain antibody to specifically recognize human Mesothelin [Poster presentation]. GIGA Day, Liège, Belgium. |